论文部分内容阅读
目的:探讨RhoC和ROCK Ⅰ基因在不同等级宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)和宫颈癌中的表达情况及二者与宫颈癌发生的相关性。方法:采用免疫组化的方法检测慢性炎症28例、CIN Ⅰ 25例、CINⅡ28例、CIN Ⅲ28例、宫颈癌27例中RhoC和ROCK Ⅰ基因的表达情况。结果:RhoC和ROCK Ⅰ在CINⅡ、CINⅢ和宫颈癌中的表达水平显著高于CIN Ⅰ和慢性炎症,病变程度越重,表达水平越高,差异有统计学意义(P<0.01)。RhoC和ROCK Ⅰ的表达在CINⅡ及以上病变中成正相关(rs=0.605,P<0.001)。结论:RhoC在表达水平较高时可能通过ROCK Ⅰ促进宫颈癌前病变的进展和宫颈癌的发生,RhoC/ROCK Ⅰ可能成为早期治疗的新靶点。宫颈组织中RhoC的表达水平有助于完善宫颈病变患者的治疗方案和评估宫颈病变的癌变风险。
Objective: To investigate the expression of RhoC and ROCK Ⅰ in cervical intraepithelial neoplasia (CIN) and cervical cancer and their relationship with cervical cancer. Methods: The expressions of RhoC and ROCK Ⅰ in 28 cases of chronic inflammation, 25 cases of CIN Ⅰ, 28 cases of CINⅡ, 28 cases of CIN Ⅲ and 27 cases of cervical cancer were detected by immunohistochemistry. Results: The expression of RhoC and ROCK Ⅰ in CINⅡ, CINⅢ and cervical cancer was significantly higher than that in CIN Ⅰ and chronic inflammation. The more severe the lesions were, the higher the expression was. The difference was statistically significant (P <0.01). The expression of RhoC and ROCK Ⅰ was positively correlated with CIN Ⅱ and above (rs = 0.605, P <0.001). CONCLUSION: RhoC may promote the progression of cervical precancerous lesions and cervical cancer through ROCK Ⅰ. RhoC / ROCK Ⅰ may be a new target for early treatment. The expression of RhoC in cervical tissue can help improve the treatment of patients with cervical lesions and assess the risk of cervical cancer.